company dropping glp-1 coverage 2025 GLP-1s and Obesity Coverage: Differing Perspectives for Employers and Health Plans GLP-1s and the Future of

injections of 100 nmol kg 1 MK-801 ( n = 7 mice and n = 4 cages), 100 nmol kg 1 GLP-1 ( n = 6 mice and n = 3 cages), 100 nmol kg 1 , GLP-1MK-801 ( n = 6 mice and n = 3 cages), co-administration of 100 nmol kg 1 GLP-1 and 100 nmol kg 1 MK-801 ( n = 6 mice and n = 3 cages) or vehicle (isotonic saline, n = 7 mice and n = 4 cages) for 14 days

Managing the dose escalation transitions The transitions from 0.5 mg to 1.0 mg and from 1.7 mg to 2.4 mg are the two points where nausea most commonly spikes

Department of Veterans Affairs Million Veteran Program

All other contributing authors of this chapter declare that they have no interests that conflict with the contents of this chapter